Association of 25‐hydroxyvitamin D status with brain volume changes

Lee, Yeonjae Angel; Yoon, Sungjin; Kim, SangYun; Youn, Young Chul

doi:10.1002/fsn3.2382

Cited by 12 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study found sarcopenia in female AD patients rather than males are more likely to have lower levels of haemoglobin and 25-hydroxyvitamin D, 56 which were associated with volumes of brain-specific areas. 57 Although our study did not investigate the joint mechanism by which the indicators related to sarcopenia and AD contribute to each other, all of the above mechanisms provided sufficient supporting evidence for the close and definite correlation between sarcopenia and AD. Future studies can consider female AD patients as research objects to explore more potential biological mechanisms.…”

Section: Discussionmentioning

confidence: 70%

Relationship between sarcopenia and sleep status in female patients with mild to moderate Alzheimer's disease

Liu

Zhuang

et al. 2022

Psychogeriatrics

View full text Add to dashboard Cite

Background: Sleep disorders and sarcopenia could contribute to the development of Alzheimer's disease (AD), which are risk factors that rapidly deteriorate cognitive functions. However, few studies have evaluated the relationship between sarcopenia and sleep disorders in female AD patients, who have a higher prevalence than male patients. This study aimed to investigate the relationship between sarcopenia and sleep status in female patients with mild to moderate AD. Methods: This cross-sectional study recruited 112 female outpatients aged between 60 and 85 years. Demographic characteristics, appendicular skeletal muscle mass index (ASMI), grip strength, and gait speed were assessed. Sarcopenia was diagnosed according to criteria of the Asian Working Group for Sarcopenia. Pittsburgh Sleep Quality Index (PSQI) assessed sleep variables. Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) assessed cognitive function. Binary logistic regression models explored the relationship between sleep variables and cognitive function and sarcopenia, adjusting for potential cofounders. Results: The outpatients were divided into 36 AD patients with sarcopenia (ADSa) and 76 AD patients without sarcopenia (ADNSa), with a prevalence of 32.1%. ADSa had lower ASMI, weaker grip strength, slower gait speed, a higher incidence of poor sleep quality and poorer cognitive function. Multivariate binary logistic regression analysis showed that high total scores of PSQI (odds ratio (OR) = 1.13), poor sleep quality (OR = 2.73), poor subjective sleep quality (OR = 1.83), low MMSE (OR = 0.77) and MoCA (OR = 0.76) scores were associated with high odds of sarcopenia. Compared to sleep time ≤ 15 min, >60 min (OR = 5.01) were associated with sarcopenia. Sleep duration <6 h (OR = 3.99), 8-9 h (OR = 4.48) and ≥9 h (OR = 6.33) were associated with sarcopenia compared to 7-8 h. Conclusions: More sleep symptoms and cognitive impairment exist in female patients with sarcopenia. The higher total scores of PSQI, poorer subjective sleep quality, longer sleep latency, excessive and insufficient sleep duration and poorer cognitive function are associated with higher odds of sarcopenia in female patients with mild to moderate AD.

show abstract

Section: Discussionmentioning

confidence: 70%

Relationship between sarcopenia and sleep status in female patients with mild to moderate Alzheimer's disease

Liu

Zhuang

et al. 2022

Psychogeriatrics

View full text Add to dashboard Cite

show abstract

“…Recent epidemiological reports have highlighted a potential association between vitamin D deficiency and AD [5,7,[18][19][20][21][22]. Moreover, vitamin D hypovitaminosis is relevant for increased risk of disease and development of cognitive impairment and AD and is associated with decreased volumes in the hippocampal regions in elderly patients with cognitive decline [3,6,[23][24][25]. These findings propose that insufficient vitamin D levels may contribute to the progression of AD, with possible implications for prevention and treatment strategies [26].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D Reduces GABA-Positive Astrocytes in the 5xFAD Mouse Model of Alzheimer’s Disease

Kang,

Park,

Kim

2024

Journal of Alzheimer’s Disease

View full text Add to dashboard Cite

Background: Vitamin D has neuroprotective and immunomodulating functions that may impact glial cell function in the brain. Previously, we reported molecular and behavioral changes caused by deficiency and supplementation of vitamin D in an Alzheimer’s disease (AD) mouse model. Recent studies have highlighted reactive astrocytes as a new therapeutic target for AD treatment. However, the mechanisms underlying the therapeutic effects of vitamin D on the glial cells of AD remain unclear. Objective: To investigate the potential association between vitamin D deficiency/supplementation and the pathological progression of AD, including amyloid-β (Aβ) pathology and reactive astrogliosis. Methods: Transgenic hemizygous 5XFAD male mice were subjected to different dietary interventions and intraperitoneal vitamin D injections to examine the effects of vitamin D deficiency and supplementation on AD. Brain tissue was then analyzed using immunohistochemistry for Aβ plaques, microglia, and astrocytes, with quantifications performed via ImageJ software. Results: Our results demonstrated that vitamin D deficiency exacerbated Aβ plaque formation and increased GABA-positive reactive astrocytes in AD model mice, while vitamin D supplementation ameliorated these effects, leading to a reduction in Aβ plaques and GABA-positive astrocytes. Conclusions: Our findings highlight the significant impact of vitamin D status on Aβ pathology and reactive astrogliosis, underscoring its potential role in the prevention and treatment of AD. This study provides the first in vivo evidence of the association between vitamin D and reactive astrogliosis in AD model mice, indicating the potential for targeting vitamin D levels as a novel therapeutic approach for AD.

show abstract

“…Moreover, epidemiological evidence demonstrates the relevance of vitamin D hypovitaminosis in the increased disease risk and progression of cognitive impairment and AD [ 44 , 45 ]. Moreover, recent reports suggest that low serum vitamin D levels are associated with decreased volumes in the hippocampal regions in elderly patients with cognitive decline [ 46 ]. Using the AD mouse model, we investigated the role of vitamin D deficiency in AD pathogenesis and cognitive function and found that a vitamin D-deficient state induced by diet led to a more significant brain Aβ load in both the early and late stages of AD progression.…”

Section: Discussionmentioning

confidence: 99%

The Role of Vitamin D in Alzheimer’s Disease: A Transcriptional Regulator of Amyloidopathy and Gliopathy

et al. 2022

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is characterized by amyloid-beta (Aβ) accumulation and cognitive mental decline. Epidemiological studies have suggested an association between low serum vitamin D levels and an increased risk of AD. Vitamin D regulates gene expression via the vitamin D receptor, a nuclear ligand-dependent transcription factor. However, the molecular mechanism underlying the pathogenic and therapeutic effects of vitamin D on AD is not fully understood yet. To better understand how vitamin D regulates the expression of genes related to AD pathology, first, we induced vitamin D deficiency in 5xFAD mice by providing a vitamin-D-deficient diet and observed the changes in the mRNA level of genes related to Aβ processing, which resulted in an increase in the Aβ load in the brain. The vitamin D-deficient diet also suppressed the expression of genes for microglial Aβ phagocytosis. Interestingly, vitamin D deficiency in the early stage of AD resulted in earlier memory impairment. In addition, we administered vitamin D intraperitoneally to 5xFAD mice with a normal diet and found lower Aβ levels with the suppressed expression of genes for Aβ generation and observed improved memory function, which may be potentially associated with reduced MAO-B expression. These findings strongly suggest the role of vitamin D as a crucial disease-modifying factor that may modulate the amyloid pathology with regard to reducing AD symptoms.

show abstract

Association of 25‐hydroxyvitamin D status with brain volume changes

Cited by 12 publications

References 60 publications

Relationship between sarcopenia and sleep status in female patients with mild to moderate Alzheimer's disease

Relationship between sarcopenia and sleep status in female patients with mild to moderate Alzheimer's disease

Vitamin D Reduces GABA-Positive Astrocytes in the 5xFAD Mouse Model of Alzheimer’s Disease

The Role of Vitamin D in Alzheimer’s Disease: A Transcriptional Regulator of Amyloidopathy and Gliopathy

Contact Info

Product

Resources

About